GHRP-6 vs Gonadorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
GHRP-6
GHRP-6 is a first-generation synthetic hexapeptide GH secretagogue that strongly stimulates pituitary GH release via ghrelin receptor activation. It is one of the oldest and most well-studied GHRPs, with a large body of research spanning more than three decades. GHRP-6 produces significant GH pulses but is notable for powerfully stimulating appetite — a side effect that can be beneficial for those in a caloric deficit or disadvantageous for those managing body composition.
Full profileGonadorelin
Synthetic form of endogenous gonadotropin-releasing hormone (GnRH) that stimulates LH and FSH release from the anterior pituitary. Used in TRT protocols to maintain testicular function and prevent atrophy during exogenous testosterone administration. Preserves spermatogenesis and endogenous testosterone production capacity.
Full profile| GHRP-6 | Gonadorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | Growth Hormone Releasing Peptide-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 | GnRH, gonadotropin-releasing hormone, Factrel, Lutrepulse |
| Evidence | Preclinical only | Research-stage |
| Dosing range | 100mcg–300mcg mcg, 1–3 times daily, on an empty stomach | 50mcg–200mcg mcg, 2–3x per week subcutaneous |
| Administration | Subcutaneous injection, Intramuscular injection | Subcutaneous injection, Intranasal (pulsatile delivery) |
| Key side effects | Strong increase in appetite (most common and notable), Elevated cortisol and prolactin at higher doses, Water retention / bloating, Fatigue at high doses | Injection site reactions, Headache, Nausea, Flushing |
| Cited sources | 3 references | 2 references |
Key differences
- Evidence level differs: GHRP-6 is preclinical only, while Gonadorelin is research-stage.
- Administration: GHRP-6 — Subcutaneous injection, Intramuscular injection; Gonadorelin — Subcutaneous injection, Intranasal (pulsatile delivery).
- Frequency: GHRP-6 is typically 1–3 times daily, on an empty stomach; Gonadorelin is 2–3x per week subcutaneous.
- Research depth: this profile cites 3 sources for GHRP-6 vs 2 for Gonadorelin.
How each works
GHRP-6
Human studies confirm GHRP-6 robustly elevates GH within 15–30 minutes of injection, with effects diminishing toward baseline within 2–3 hours. Chronic use increases baseline IGF-1. Research also indicates mild stimulation of cortisol and prolactin, particularly at higher doses. Animal models have shown potential cardioprotective, hepatoprotective, and muscle-sparing effects, though human equivalents are not established.
Gonadorelin
Gonadorelin directly binds GnRH receptors in the anterior pituitary to trigger LH and FSH secretion, which in turn stimulates Leydig cells for testosterone production and maintains spermatogenesis. Used as a TRT adjunct, pulsatile gonadorelin administration mimics natural hypothalamic GnRH to prevent testicular suppression associated with exogenous androgen use.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.